TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
TWD 9.68
(-9.95%)
TWD 9.68
(-9.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 136.73 Million TWD | 157.65% |
| 2022 | -237.16 Million TWD | -130.58% |
| 2021 | 775.61 Million TWD | 291.6% |
| 2020 | -404.81 Million TWD | -36.91% |
| 2019 | -295.68 Million TWD | 13.85% |
| 2018 | -343.21 Million TWD | -145.98% |
| 2017 | 746.37 Million TWD | 398.51% |
| 2016 | -250.03 Million TWD | 39.46% |
| 2015 | -412.99 Million TWD | -2.3% |
| 2014 | -403.71 Million TWD | 6.59% |
| 2013 | -432.19 Million TWD | 7.73% |
| 2012 | -468.39 Million TWD | -1193.44% |
| 2011 | 42.83 Million TWD | 101.87% |
| 2010 | -2.28 Billion TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -6.16 Million TWD | -103.32% |
| 2024 Q2 | 64.2 Million TWD | 1141.34% |
| 2023 Q3 | -8.55 Million TWD | -185.52% |
| 2023 FY | 136.73 Million TWD | 157.65% |
| 2023 Q1 | -50.23 Million TWD | 55.25% |
| 2023 Q2 | 10 Million TWD | 119.91% |
| 2023 Q4 | 185.67 Million TWD | 2270.58% |
| 2022 Q3 | 10.79 Million TWD | 110.53% |
| 2022 FY | -237.16 Million TWD | -130.58% |
| 2022 Q1 | -33.18 Million TWD | 76.22% |
| 2022 Q2 | -102.5 Million TWD | -208.86% |
| 2022 Q4 | -112.26 Million TWD | -1140.39% |
| 2021 Q4 | -139.56 Million TWD | 1.46% |
| 2021 FY | 775.61 Million TWD | 291.6% |
| 2021 Q2 | 1.1 Billion TWD | 2620.87% |
| 2021 Q3 | -141.62 Million TWD | -112.87% |
| 2021 Q1 | -43.65 Million TWD | 66.49% |
| 2020 Q3 | -99.43 Million TWD | 3.4% |
| 2020 Q1 | -72.17 Million TWD | 63.79% |
| 2020 Q4 | -130.26 Million TWD | -31.01% |
| 2020 FY | -404.81 Million TWD | -36.91% |
| 2020 Q2 | -102.93 Million TWD | -42.62% |
| 2019 Q3 | -102.75 Million TWD | -269.96% |
| 2019 Q1 | -54.07 Million TWD | 43.52% |
| 2019 Q2 | 60.45 Million TWD | 211.79% |
| 2019 Q4 | -199.31 Million TWD | -93.98% |
| 2019 FY | -295.68 Million TWD | 13.85% |
| 2018 Q1 | -25.46 Million TWD | 80.54% |
| 2018 Q4 | -95.75 Million TWD | 23.14% |
| 2018 Q3 | -124.57 Million TWD | -27.87% |
| 2018 Q2 | -97.42 Million TWD | -282.63% |
| 2018 FY | -343.21 Million TWD | -145.98% |
| 2017 FY | 746.37 Million TWD | 398.51% |
| 2017 Q2 | 976.08 Million TWD | 1870.39% |
| 2017 Q1 | -55.13 Million TWD | 1.34% |
| 2017 Q3 | -43.71 Million TWD | -104.48% |
| 2017 Q4 | -130.85 Million TWD | -199.32% |
| 2016 Q2 | -34.79 Million TWD | 63.02% |
| 2016 Q3 | -65.25 Million TWD | -87.53% |
| 2016 FY | -250.03 Million TWD | 39.46% |
| 2016 Q4 | -55.88 Million TWD | 14.36% |
| 2016 Q1 | -94.09 Million TWD | 21.24% |
| 2015 Q2 | -107.77 Million TWD | -27.33% |
| 2015 Q4 | -119.47 Million TWD | -18.17% |
| 2015 Q3 | -101.1 Million TWD | 6.19% |
| 2015 Q1 | -84.64 Million TWD | 25.49% |
| 2015 FY | -412.99 Million TWD | -2.3% |
| 2014 Q2 | -131.44 Million TWD | -117.03% |
| 2014 Q1 | -60.56 Million TWD | 62.23% |
| 2014 Q4 | -113.59 Million TWD | -15.79% |
| 2014 FY | -403.71 Million TWD | 6.59% |
| 2014 Q3 | -98.1 Million TWD | 25.37% |
| 2013 Q2 | -80.62 Million TWD | -79.01% |
| 2013 Q4 | -160.33 Million TWD | -9.67% |
| 2013 Q3 | -146.2 Million TWD | -81.34% |
| 2013 FY | -432.19 Million TWD | 7.73% |
| 2013 Q1 | -45.03 Million TWD | 71.08% |
| 2012 Q4 | -155.73 Million TWD | -24.23% |
| 2012 Q3 | -125.36 Million TWD | 0.0% |
| 2012 FY | -468.39 Million TWD | -1193.44% |
| 2011 FY | 42.83 Million TWD | 101.87% |
| 2010 FY | -2.28 Billion TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd | -51.78 Million TWD | 364.051% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 251.01 Million TWD | 45.528% |
| Level Biotechnology Inc. | 62.9 Million TWD | -117.361% |
| Sagittarius Life Science Corp | -55.03 Million TWD | 348.426% |
| NeoCore Technology Co., Ltd. | -64.64 Million TWD | 311.511% |
| TaiMed Biologics Inc. | -194.81 Million TWD | 170.187% |
| GlycoNex Incorporation | -178.36 Million TWD | 176.659% |
| VBI | -6.6 Million TWD | 2171.368% |
| GeneReach Biotechnology Corp. | -166.27 Million TWD | 182.234% |
| Taiwan Advance Bio-Pharmaceutical Inc. | -10.68 Million TWD | 1380.013% |
| SynCore Biotechnology Co.,Ltd | -38.17 Million TWD | 458.197% |
| Genomics BioSci & Tech. Co.,Ltd. | -168.06 Million TWD | 181.356% |
| Visgeneer Inc. | -19.58 Million TWD | 797.999% |
| Mycenax Biotech Inc. | -682.84 Million TWD | 120.024% |
| Sunmax Biotechnology Co., Ltd. | 625.7 Million TWD | 78.148% |
| G&E Herbal Biotechnology Co., Ltd. | 72.4 Million TWD | -88.855% |
| Neith Corporation | -40.03 Million TWD | 441.546% |
| Medigen Vaccine Biologics Corporation | -1.15 Billion TWD | 111.789% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -6.04 Million TWD | 2361.138% |
| Enimmune corporation | -223.74 Million TWD | 161.111% |
| TaiRx, Inc. | -212.29 Million TWD | 164.407% |
| CHO Pharma, Inc. | -306.08 Million TWD | 144.671% |
| EirGenix Inc. | -915.2 Million TWD | 114.94% |
| BioLASCO Taiwan Co., Ltd. | 49.74 Million TWD | -174.875% |
| Sunny Pharmtech Inc. | -63.32 Million TWD | 315.937% |
| Lin BioScience, Inc. | -687.19 Million TWD | 119.897% |
| BioGend Therapeutics Co., Ltd. | -156.32 Million TWD | 187.466% |
| Feng Chi Biotech Corp. | 22.79 Million TWD | -499.908% |
| Bio Preventive Medicine Corp. | -73.28 Million TWD | 286.574% |
| Lukas Biomedical Inc. | -47.35 Million TWD | 388.748% |
| RBC Bioscience Corporation | 6.43 Million TWD | -2026.454% |
| BiOptic Inc. | 37.74 Million TWD | -262.23% |
| BRIM Biotechnology, Inc. | -688.02 Million TWD | 119.873% |
| Shine-On BioMedical Co.,Ltd. | -37.16 Million TWD | 467.903% |
| Great Novel Therapeutics Biotech & Medicals | -61.54 Million TWD | 322.182% |
| Syngen Biotech Co.,Ltd. | 274.82 Million TWD | 50.248% |
| Advagene Biopharma Co., Ltd. | -92.11 Million TWD | 248.443% |
| NaviFUS Corp. | -65.72 Million TWD | 308.022% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -88.08 Million TWD | 255.219% |
| Sinew Pharma Inc. | -170.92 Million TWD | 179.997% |
| Andros Pharmaceuticals Co.,Ltd | -68.15 Million TWD | 300.606% |
| Greenyn Biotechnology Co., Ltd | 130.66 Million TWD | -4.643% |
| Lumosa Therapeutics Co., Ltd. | -238.04 Million TWD | 157.44% |
| AP Biosciences Inc | -339.29 Million TWD | 140.299% |
| Medigen Biotechnology Corp. | -561.29 Million TWD | 124.36% |
| 3D Global Biotech Inc. | -57.95 Million TWD | 335.942% |
| Pharmosa Biopharm Inc. | 8.45 Million TWD | -1516.97% |
| Intech Biopharm Corporation | -337.98 Million TWD | 140.455% |
| Oneness Biotech Co., Ltd. | -1.31 Billion TWD | 110.415% |
| Eusol Biotech Co.,Ltd. | -51.61 Million TWD | 364.916% |
| TWi Biotechnology, Inc. | -170.68 Million TWD | 180.108% |
| Ever Supreme Bio Technology Co., Ltd | 539.39 Million TWD | 74.651% |
| TCI GENE Inc. | 11.67 Million TWD | -1071.344% |
| MegaPro Biomedical Co., Ltd | -127.54 Million TWD | 207.2% |
| Senhwa Biosciences, Inc. | -296.3 Million TWD | 146.145% |
| Taiwan Bio Therapeutics Co., Ltd | -217.51 Million TWD | 162.861% |
| NatureWise Biotech & Medicals Corporation | 10.12 Million TWD | -1251.097% |
| PharmaEngine, Inc. | 274.65 Million TWD | 50.216% |
| Savior Lifetec Corporation | 30.03 Million TWD | -355.315% |
| OBI Pharma, Inc. | -1.04 Billion TWD | 113.066% |
| Meribank Biotech Co., Ltd | -125.34 Million TWD | 209.083% |
| Acepodia, Inc. | -817.31 Million TWD | 116.729% |
| Caliway Biopharmaceuticals Co., Ltd. | -488.45 Million TWD | 127.993% |